NCT03109925View on ClinicalTrials.gov

Use of a Novel Radiopaque Embolic Agent in Prostatic Artery Embolisation for Symptomatic Benign Prostatic Enlargement

PHASE2UnknownINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

June 2, 2017

Primary Completion Date

June 29, 2021

Study Completion Date

June 29, 2021

Conditions

Benign Prostatic Hyperplasia

Interventions

DEVICE

DC Lumi Bead, BTG

Embolic agent which is radio-opaque

Trial Locations (1)

Unknown

RECRUITING

Southampton General Hospital, University Hospital Southampton, Southampton

Sponsors

Collaborators (1)

BTG International Inc.

All Listed Sponsors

collaborator

BTG International Inc.

OTHER

lead

University Hospital Southampton NHS Foundation Trust

OTHER

NCT03109925 - Use of a Novel Radiopaque Embolic Agent in Prostatic Artery Embolisation for Symptomatic Benign Prostatic Enlargement | Biotech Hunter | Biotech Hunter